论文部分内容阅读
目的 :观察造血生长因子对骨髓CD34 +细胞的扩增效应及扩增细胞的分化特性。方法 :采用重组人白细胞介素 (rhIL) 1 +rhIL 3+rhIL6 +重组人粒细胞集落刺激因子 +重组人粒 巨噬细胞集落刺激因子和重组人干细胞因子对人骨髓单个核细胞 (MNC)进行刺激 ,动态观察了经上述细胞因子作用后MNC的增殖效应及液态扩增培养后粒 巨噬集落形成率 (CFU GM ) ,利用流式细胞技术 (FACS)分析了扩增前后CD34 +细胞及其亚群的动态变化。结果 :经上述 6种细胞因子作用 2 4d ,骨髓MNC总数是原代MNC的 38.33倍 ,液态扩增 1 0d后 ,CFU GM的数量达高峰 ,是原代MNC的 1 9.0 4倍 ,2 4d时CFU GM总数降至 3.94倍 ,且集落明显小于扩增初期。扩增至 6～ 1 0d ,CD34 +细胞总数是原代MNC的 1 36 .40～ 90 .40倍 ,1 9d时降为 6 1 .40倍。结论 :外源性造血生长因子对CD34 +骨髓细胞具有较强的扩增效应 ,选择适宜的扩增时间是保证骨髓移植后尽快重建造血功能的重要环节。
Objective: To observe the amplification effect of hematopoietic growth factor on bone marrow CD34 + cells and the differentiation characteristics of the expanded cells. Methods: Human bone marrow mononuclear cells (MNC) were transfected with recombinant human interleukin (rhIL) 1 + rhIL 3 + rhIL6 + recombinant human granulocyte colony-stimulating factor + recombinant human granulocyte-macrophage colony stimulating factor and recombinant human stem cell factor Stimulated and dynamically observed the proliferative effect of MNC by the above cytokines and granulocyte macrophage colony formation rate (CFU GM) after liquid amplification culture, and analyzed the expression of CD34 + cells before and after expansion by flow cytometry (FACS) Subsets of the dynamic changes. RESULTS: After treated with the above six cytokines for 24 days, the total number of bone marrow MNCs was 38.33 times that of the primary MNCs. After the liquid state was expanded for 10 days, the number of CFU GM reached a peak of 9.04 times that of the primary MNCs. After 24 days The total number of CFU GM decreased 3.94 times, and the colony was significantly less than the initial amplification. After 6-10d, the total number of CD34 + cells was 136.34-90.40 times that of the primary MNC, and decreased to 6.14-fold on the 9th day. Conclusion: Exogenous hematopoietic growth factor has a strong amplification effect on CD34 + myeloid cells. Choosing an appropriate time for amplification is an important step to ensure the hematopoietic function reconstructed as soon as possible after bone marrow transplantation.